[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR034132A1 - Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica - Google Patents

Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica

Info

Publication number
AR034132A1
AR034132A1 ARP010103642A ARP010103642A AR034132A1 AR 034132 A1 AR034132 A1 AR 034132A1 AR P010103642 A ARP010103642 A AR P010103642A AR P010103642 A ARP010103642 A AR P010103642A AR 034132 A1 AR034132 A1 AR 034132A1
Authority
AR
Argentina
Prior art keywords
agent
insulin
production
pharmaceutical composition
somatostatine
Prior art date
Application number
ARP010103642A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034132(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR034132A1 publication Critical patent/AR034132A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Un análogo de somatostatina, que comprende compuesto de la fórmula (1) estando uno de los grupos amino opcionalmente en forma protegida, o una salo complejo del mismo; un proceso para su producción y una composición farmacéutica que es para utilizarse en combinación con un agente inmunosupresor, un agente anti-inflamatorio, un agente modulador de receptor de secretagogo de hormona de crecimiento, un antagonista del receptor de hormona de crecimiento, un secretagogo de insulina, un potenciador de la secreción de insulina, un sensibilizante de insulina, una dosis baja de insulina, un agente que tenga efectos anti-angiogenéticos, o un agente quimioterapéutico.
ARP010103642A 2000-08-01 2001-07-30 Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica AR034132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018891.2A GB0018891D0 (en) 2000-08-01 2000-08-01 Organic compounds

Publications (1)

Publication Number Publication Date
AR034132A1 true AR034132A1 (es) 2004-02-04

Family

ID=9896782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103642A AR034132A1 (es) 2000-08-01 2001-07-30 Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica

Country Status (36)

Country Link
US (5) US7473761B2 (es)
EP (1) EP1307486B1 (es)
JP (1) JP3829118B2 (es)
KR (2) KR100799394B1 (es)
CN (1) CN1267451C (es)
AR (1) AR034132A1 (es)
AT (1) ATE393782T1 (es)
AU (2) AU8977801A (es)
BE (1) BE2012C026I2 (es)
BR (1) BRPI0112859B8 (es)
CA (1) CA2416293C (es)
CY (2) CY1108547T1 (es)
CZ (1) CZ302461B6 (es)
DE (1) DE60133823T2 (es)
DK (1) DK1307486T3 (es)
EC (1) ECSP034456A (es)
ES (1) ES2305104T3 (es)
FR (1) FR12C0041I2 (es)
GB (1) GB0018891D0 (es)
HK (1) HK1057051A1 (es)
HU (1) HU227812B1 (es)
IL (2) IL153920A0 (es)
LU (1) LU92024I2 (es)
MX (1) MXPA03000991A (es)
MY (1) MY138074A (es)
NO (2) NO331093B1 (es)
NZ (1) NZ523836A (es)
PE (1) PE20020176A1 (es)
PL (1) PL204161B1 (es)
PT (1) PT1307486E (es)
RU (1) RU2287533C2 (es)
SI (1) SI1307486T1 (es)
SK (1) SK287798B6 (es)
TW (1) TWI282341B (es)
WO (1) WO2002010192A2 (es)
ZA (1) ZA200300406B (es)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
ES2341336T3 (es) 2002-12-12 2010-06-18 Novartis Ag Procedimiento para la sintesis de peptidos que contienen una subestructura de 4-hidroxiprolina.
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0314695D0 (en) * 2003-06-24 2003-07-30 Novartis Ag Organic compounds
AR044852A1 (es) 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0318682D0 (en) * 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (fr) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
RU2008151727A (ru) * 2006-06-08 2010-07-20 Новартис АГ (CH) Комбинация аналогов соматостатина с антагонистом рецептора дофамина или рецептора гормона роста
US7697338B2 (en) * 2006-11-16 2010-04-13 Sandisk Corporation Systems for controlled boosting in non-volatile memory soft programming
WO2008064570A1 (en) * 2006-11-28 2008-06-05 The University Of Hong Kong The use of granulin-epithelin precursor (gep) antibodies for detection and suppression of hepatocellular carcinoma (hcc)
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
EP2142562B1 (en) 2007-03-28 2013-07-03 President and Fellows of Harvard College Stitched polypeptides
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
WO2009009035A1 (en) * 2007-07-06 2009-01-15 Ipsen Pharma S.A.S. Somatostatin analog and uses thereof
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
RU2523416C2 (ru) * 2007-11-28 2014-07-20 Новартис Аг Применение аналогов соматостатина при менингиоме
KR101500528B1 (ko) * 2007-12-03 2015-03-09 이탈파마코 에스.피.에이. 새로운 비-선택적 소마토스타틴 유사체
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
US9314508B2 (en) * 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
MX348705B (es) 2008-09-17 2017-06-26 Chiasma Inc Composiciones farmacéuticas y métodos de administración relacionados.
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012074559A2 (en) 2010-12-02 2012-06-07 New York University Treatment of non-proliferative cystic disease
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2651917A1 (en) 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
US20130035054A1 (en) * 2011-07-14 2013-02-07 Faceon Mobile Phone with multi-portal access for display during incoming and outgoing call
WO2013019923A2 (en) 2011-08-02 2013-02-07 New York University Methods for detecting progenitor cells and uses thereof
UA111503C2 (uk) 2011-09-27 2016-05-10 Новартіс Аг 3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
EA201491105A1 (ru) 2011-12-05 2014-09-30 Новартис Аг Циклические производные мочевины в качестве антагонистов андрогенных рецепторов
DK2787975T3 (da) 2011-12-05 2017-11-20 Camurus Ab Robuste formuleringer med kontrolleret frigivelse
JP6158833B2 (ja) 2012-01-09 2017-07-05 アローヘッド ファーマシューティカルズ インコーポレイテッド ベータ−カテニン関連疾患を処置するための有機組成物
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
BR112014029425A2 (pt) * 2012-05-25 2017-06-27 Camurus Ab pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
BR112015018882B1 (pt) 2013-02-19 2021-09-14 Novartis Ag Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
US20160039802A1 (en) 2013-03-14 2016-02-11 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
EP3082765B1 (en) 2013-12-19 2018-08-01 Novartis AG Drug delivery systems
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
CN112245565A (zh) 2014-09-24 2021-01-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US10508108B2 (en) 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089833A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
EP3229824A4 (en) 2014-12-10 2018-07-11 Chiasma Inc. Oral octreotide administered in combination with other therapeutic agents
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
US20210317161A1 (en) 2014-12-19 2021-10-14 Auro Peptides Ltd A process for the preparation of pasireotide
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016162127A1 (en) * 2015-04-08 2016-10-13 Polyphor Ag Backbone-cyclized peptidomimetics
CN108368147A (zh) 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10556924B2 (en) 2015-06-22 2020-02-11 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of pasireotide
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
TWI696629B (zh) 2015-08-13 2020-06-21 美商默沙東藥廠 作為ｓｔｉｎｇ促效劑之環狀雙核苷酸化合物
CN116059344A (zh) 2015-11-03 2023-05-05 詹森生物科技公司 特异性结合pd-1的抗体及其用途
EP3389783B1 (en) 2015-12-15 2024-07-03 Merck Sharp & Dohme LLC Novel compounds as indoleamine 2,3-dioxygenase inhibitors
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3452465B1 (en) 2016-05-04 2020-11-04 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN110036001B (zh) 2016-10-04 2022-03-22 默沙东公司 作为STING激动剂的苯并[b]噻吩化合物
EP3541825A1 (en) 2016-11-21 2019-09-25 Idenix Pharmaceuticals LLC. Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
WO2018138684A1 (en) 2017-01-27 2018-08-02 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
WO2018138685A2 (en) 2017-01-27 2018-08-02 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019027858A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
US11052065B2 (en) 2017-09-27 2021-07-06 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
WO2019078968A2 (en) * 2017-10-18 2019-04-25 Angex Pharmaceutical, Inc. CYCLIC COMPOUNDS AS IMMUNOMODULATORS
WO2019089412A1 (en) 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2020004930A (es) 2017-11-14 2020-08-27 Merck Sharp & Dohme Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
ES2927194T3 (es) 2017-12-15 2022-11-03 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de STING
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
AU2019248545B2 (en) 2018-04-03 2022-08-11 Merck Sharp & Dohme Llc Benzothiophenes and related compounds as sting agonists
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019231870A1 (en) 2018-05-31 2019-12-05 Merck Sharp & Dohme Corp. Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
EP3853234A1 (en) 2018-09-18 2021-07-28 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
BR112021005513A2 (pt) 2018-09-25 2021-06-22 Black Diamond Therapeutics, Inc. derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
JP2022502496A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
BR112021005606A2 (pt) 2018-09-29 2021-06-22 Novartis Ag processo de produção de um composto para inibir a atividade de shp2
WO2020092183A1 (en) 2018-11-01 2020-05-07 Merck Sharp & Dohme Corp. Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
WO2020096871A1 (en) 2018-11-06 2020-05-14 Merck Sharp & Dohme Corp. Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
EP3886845B1 (en) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
TW202120500A (zh) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CA3156370A1 (en) 2019-10-28 2021-05-06 Wenhu Duan Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
AU2021268614A1 (en) 2020-05-06 2022-12-08 Merck Sharp & Dohme Llc IL4I1 inhibitors and methods of use
IL303661A (en) 2020-12-22 2023-08-01 Nikang Therapeutics Inc COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
WO2022219412A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022219407A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
TW202346292A (zh) 2022-03-28 2023-12-01 美商尼坎醫療公司 作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2024047112A1 (en) * 2022-08-30 2024-03-07 Somtheranostics Sarl Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity
WO2024102849A1 (en) 2022-11-11 2024-05-16 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2024206357A1 (en) 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
US4505897A (en) 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
DE69434832D1 (de) 1993-06-23 2006-10-05 Diatide Inc Radioaktiv-markierte Peptidderivate des Somatostatins zur bildformenden und therapeutischen Verwendung
SI9420051A (en) 1993-08-09 1996-12-31 Biomeasure Inc Chemical modified peptide derivatives, process for their preparation and their use in human therapy
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
IT1277391B1 (it) 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
AU2764797A (en) 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP3829118B2 (ja) 2006-10-04
SK287798B6 (sk) 2011-10-04
HU227812B1 (hu) 2012-03-28
NO2012012I2 (no) 2012-07-30
US20150218223A1 (en) 2015-08-06
ES2305104T3 (es) 2008-11-01
SK1212003A3 (en) 2003-08-05
KR100799394B1 (ko) 2008-01-30
PT1307486E (pt) 2008-07-31
TWI282341B (en) 2007-06-11
FR12C0041I1 (es) 2012-07-27
PL358718A1 (en) 2004-08-09
WO2002010192A3 (en) 2002-09-19
WO2002010192A9 (en) 2002-10-17
AU2001289778B2 (en) 2005-02-03
SI1307486T1 (sl) 2008-08-31
EP1307486A2 (en) 2003-05-07
CN1446229A (zh) 2003-10-01
DK1307486T3 (da) 2008-08-25
LU92024I2 (fr) 2012-08-20
NZ523836A (en) 2004-08-27
HK1057051A1 (en) 2004-03-12
CZ302461B6 (cs) 2011-06-01
HUP0300684A3 (en) 2004-08-30
ATE393782T1 (de) 2008-05-15
PE20020176A1 (es) 2002-03-26
US9035021B2 (en) 2015-05-19
NO20030484L (no) 2003-03-19
ECSP034456A (es) 2003-03-10
CY2012018I1 (el) 2015-10-07
CZ2003288A3 (cs) 2003-05-14
US20110166320A1 (en) 2011-07-07
PL204161B1 (pl) 2009-12-31
IL153920A (en) 2010-12-30
BR0112859A (pt) 2003-07-01
NO331093B1 (no) 2011-10-03
EP1307486B1 (en) 2008-04-30
ZA200300406B (en) 2004-04-02
MY138074A (en) 2009-04-30
CY2012018I2 (el) 2015-10-07
CA2416293C (en) 2011-05-10
GB0018891D0 (en) 2000-09-20
IL153920A0 (en) 2003-07-31
US7473761B2 (en) 2009-01-06
FR12C0041I2 (fr) 2013-01-11
US20050014686A1 (en) 2005-01-20
JP2004505095A (ja) 2004-02-19
DE60133823D1 (de) 2008-06-12
US20090069225A1 (en) 2009-03-12
KR20060035809A (ko) 2006-04-26
BRPI0112859B8 (pt) 2021-05-25
BRPI0112859B1 (pt) 2016-03-01
DE60133823T2 (de) 2009-05-20
CN1267451C (zh) 2006-08-02
CY1108547T1 (el) 2014-04-09
NO2012012I1 (no) 2012-06-29
CA2416293A1 (en) 2002-02-07
KR20030033008A (ko) 2003-04-26
NO20030484D0 (no) 2003-01-30
HUP0300684A2 (hu) 2003-09-29
RU2287533C2 (ru) 2006-11-20
AU8977801A (en) 2002-02-13
US20110172157A1 (en) 2011-07-14
US8822637B2 (en) 2014-09-02
WO2002010192A2 (en) 2002-02-07
MXPA03000991A (es) 2003-06-09
US7939625B2 (en) 2011-05-10
BE2012C026I2 (es) 2020-12-15

Similar Documents

Publication Publication Date Title
AR034132A1 (es) Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
AR036813A1 (es) Composiciones farmaceuticas
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
SE8305485D0 (sv) Galenic compositions comprising calcitonin and their use
AR031067A1 (es) Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma.
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
LV5794A4 (lv) Nonapeptidi ar bombezina antagonistu ipasibam
ATE219061T1 (de) Huperzin a analoge verbindungen
EE03180B1 (et) Bombesiini antagonistpeptiidid, farmatseutiline kompositsioon ja kasutamine
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
MY135646A (en) Indolyl derivatives
DE60319707D1 (de) Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
ES2083708T3 (es) Nuevas piperazinilalcoil-3 dihidro-2,3,4h-benzoxazina-1,3 onas-4 sustituidas, su preparacion y su aplicacion en terapeutica.
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
HUP9901208A2 (hu) (R)-5-Bróm-n-(1-etil-4-metil-hexahidro-1H-1,4-diazepin-6-il)-2-metoxi-6-(metil-amino)-3-piridin-karboxamid, eljárás előállítására és ezt a vegyületet tartalmazó gyógyászati készítmény
UY26211A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas
UY26176A1 (es) Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.
AR012601A1 (es) Derivados de amidina, formulaciones farmaceuticas que los contiene, uso de dichos derivados en la preparacion de medicamentos y proceso para lapreparacion de dichos derivados
HUP9602024A2 (hu) Aminosavtartalmú, külsőlegesen használható, gyógyhatású készítmény
DE3264906D1 (en) Aminoglycoside derivatives, processes for their production, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals
GB1463505A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant, registration